首页> 美国卫生研究院文献>Frontiers in Neurology >Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial
【2h】

Post-hoc Analysis of Outcome of Intravenous Thrombolysis in Infarcts of Infratentorial Localization in the WAKE-UP Trial

机译:在唤醒试验中对腔内定位梗死的患者进行静脉溶栓治疗的事后分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Introduction: In WAKE-UP (Efficacy and Safety of MRI-based Thrombolysis in Wake-Up Stroke), patients with an acute stroke of unknown onset time were randomized to treatment with intravenous alteplase or placebo, guided by MRI.>Methods: In this exploratory post-hoc secondary analysis we compared clinical and imaging data, as well as treatment effects and safety of intravenous thrombolysis between patients with infra- vs. supratentorial stroke.>Results: Forty-eight out of 503 randomized patients (9.5%) presented with a stroke involving the cerebellum or brainstem. Patients with infratentorial stroke were younger compared to patients with supratentorial stroke (mean age 60 vs. 66 years), more frequently male (85 vs. 62%), and less severely affected (median NIHSS 4.5 vs. 6.0). There was no heterogeneity for treatment effect between supratentorial (OR 1.67 95% CI 1.11–2.51) and infratentorial (OR 1.31 95% CI 0.41–4.22) sub-groups (test for interaction p = 0.70). In patients with infratentorial stroke, favorable outcome [a score of 0–1 on the modified Rankin scale (mRS) at 90 days] was observed in 12/22 patients (54.5%) in the alteplase group and in 13/25 patients (52.0%) in the placebo group (p = 0.59). The primary safety endpoint (death or mRS 4–6 at day 90) occurred in three patients of the alteplase group (13.6%) and three patients in the placebo group (12.0%); p = 0.74.>Discussion: WAKE-UP was underpowered for demonstrating treatment effect in subgroup analyses however, based on our current results, there is no evidence to recommend withholding MRI-guided thrombolysis in patients with unknown onset stroke of infratentorial localization.
机译:>简介:在WAKE-UP(基于MRI的中风溶栓治疗的有效性和安全性)中,将具有未知起病时间的急性中风患者随机分配接受静脉内阿替普酶或安慰剂治疗, MRI。>方法:在这项探索性的事后分析中,我们比较了临床和影像学数据,以及下室上性和幕上性中风患者之间静脉溶栓的治疗效果和安全性。>结果:在503名随机分组的患者中,有48名(9.5%)出现了涉及小脑或脑干的中风。幕下中风的患者比幕上中风的患者年轻(平均年龄为60岁对66岁),男性更频繁(85岁对62%),受影响较小(NIHSS中位数为4.5对6.0)。幕上组(OR 1.67 95%CI 1.11–2.51)和下腹肌(OR 1.31 95%CI 0.41–4.22)亚组之间的治疗效果没有异质性(相互作用的检验p = 0.70)。在幕下卒中患者中,阿替普酶组和13/25患者(52.0)在12/22患者(54.5%)中观察到良好的预后[在90天时改良兰金评分(mRS)为0-1分]安慰剂组(p = 0.59)。主要安全终点(90天时死亡或mRS 4-6)发生在阿替普酶组的3例患者(13.6%)和安慰剂组的3例患者(12.0%)中; p = 0.74。>讨论:在亚组分析中,WAKE-UP不足以证明治疗效果,但是,根据我们目前的结果,没有证据建议在中风未知的患者中停用MRI指导的溶栓治疗下的定位。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号